Clonal hematopoiesis and atherosclerotic cardiovascular disease: Clinical implications, biological mechanisms, and emerging therapeutic strategies.
Clonal hematopoiesis (CH), defined by the age-related expansion of hematopoietic stem cells harboring somatic driver mutations, has emerged as a novel and clinically relevant contributor to atherosclerotic cardiovascular disease (ASCVD). Once considered primarily a precursor to hematologic malignancy, CH is now recognized as a systemic pro-inflammatory state linking somatic evolution to cardiovascular pathology.
Clonal hematopoiesis (CH), defined by the age-related expansion of hematopoietic stem cells harboring somatic driver mutations, has emerged as a novel and clinically relevant contributor to atherosclerotic cardiovascular disease (ASCVD). Once considered primarily a precursor to hematologic malignancy, CH is now recognized as a systemic pro-inflammatory state linking somatic evolution to cardiovascular pathology.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Formos Med Assoc
Why it surfaced
Matched watchlist topic 'Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)'. Study design: Review. Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.